Allergan gets US FDA nod for Botox to treat form of urinary incontinence
There was a boost for US specialty drug firm Allergan (NYSE: AGN) yesterday when the company revealed that it has received approval from the Food and Drug Administration for Botox (onabotulinum toxin A) injection, better known as a facial wrinkle reducer, to treat urinary incontinence in people with neurologic conditions such as spinal cord injury and multiple sclerosis who have over-activity of the bladder. The firm’s shares rose 3% to $77.90.
Botox, which is also cleared for the treatment of migraine and gained approval for the UI indication in Ireland last month and gained a positive opinion from European Union regulators this month (The Pharma Letter August 9), generated sales of $1.4 billion in 2010, could produce annual revenues of $40 million by 2017 for the treatment of incontinence in people with MS and spinal cord injuries, according to Leerink Swann analyst Seamus Fernandez.
Bodes well for further indications
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze